Intensity Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A novel cancer therapy using a supramolecular complex is showing promising results in phase II and III trials, with improved survival and safety outcomes. The company has secured key regulatory designations, maintains strong financial health, and is actively pursuing partnerships.
-
R&D and G&A expenses rose in Q2 2026, driving a 19% increase in net loss. Clinical trial enrollment resumed for both INVINCIBLE-3 and INVINCIBLE-4, with promising early efficacy data in TNBC. Additional capital is needed to fully activate sites and accelerate trial progress.
-
The meeting saw the re-election of two directors, approval of auditor ratification, and amendments to stock plans. All proposals passed by majority vote, and no questions were raised during the Q&A session.
Fiscal Year 2025
-
INT230-6, an intratumoral therapy combining SHAO, cisplatin, and vinblastine, showed high tumor retention, favorable safety, and promising efficacy in metastatic solid tumors, especially when ≥40% of tumor burden was injected. Median overall survival reached 12–19 months, with evidence of immune activation and abscopal effects.
-
Stockholders approved both a reverse stock split and an adjournment proposal, with the Board retaining discretion over the timing and ratio of the split. Final voting results will be disclosed in a Form 8-K. Forward-looking statements were noted as subject to risk factors.
-
The meeting confirmed a quorum, elected Dr. Mark A. Goldberg as Director through 2028, and ratified EisnerAmper LLP as auditors for 2025. No questions were raised by stockholders, and management highlighted standard forward-looking statement risks.
Fiscal Year 2024
-
The meeting saw the re-election of two directors, approval of the 2024 Employee Stock Purchase Plan, and ratification of the auditor. A quorum was present, and all proposals passed by majority vote. No questions were raised during the Q&A.